Following this reasoning we would suggest using the “gene name encephalopathy” nomenclature just as if we were encountering a genetic mutation in an unknown syndrome, such as with the CHD2 genes, while in a well-known syndrome, such as Dravet Syndrome or Othahara syndrome, we suggest using the “syndrome name, gene name encephalopathy” nomenclature, for instance “Dravet syndrome, SCN2A encephalopathy” or “Othahara syndrome, SCN2A encephalopathy”, and“Othahara syndrome, KCNQ2 encephalopathy” or “ESES syndrome, KCNQ2 encephalopathy”. Here, CHD2 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.